Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 4:07 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 708 matching trials from the live ClinicalTrials.gov search.
Conditions
Multiple Myeloma
Interventions
GCS-100, Bortezomib/Dexamethasone
Drug
Lead sponsor
La Jolla Pharmaceutical Company
Industry
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
3
States / cities
Gainesville, Florida • Boston, Massachusetts • Milwaukee, Wisconsin
Conditions
Diabetic Macular Edema
Interventions
Dexamethasone, Sham
Drug · Other
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
494 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
1
States / cities
Inglewood, California
Conditions
COVID 19, ARDS
Interventions
Stellate Ganglion Block
Drug
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years to 85 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Omaha, Nebraska
Conditions
Lymphoma
Interventions
Radiation Therapy, Dexamethasone, Etoposide phosphate, Ifosfamide, Mesna, Carboplatin
Radiation · Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2034
U.S. locations
1
States / cities
Houston, Texas
Conditions
Multiple Myeloma and Plasma Cell Neoplasm
Interventions
ascorbic acid, arsenic trioxide, bortezomib, dexamethasone, thalidomide, Aspirin
Dietary Supplement · Drug
Lead sponsor
Barbara Ann Karmanos Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Detroit, Michigan
Conditions
Sudden Sensorineural Hearing Loss (SSNHL)
Interventions
Dexamethasone, Prednisone
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
1
States / cities
Aurora, Colorado
Conditions
Multiple Myeloma
Interventions
Pomalidomide, Carfilzomib, dexamethasone, Daratumumab
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2025
U.S. locations
4
States / cities
Chicago, Illinois • Ann Arbor, Michigan • Detroit, Michigan + 1 more
Conditions
Acute Lymphoblastic Leukemia, Adult B Acute Lymphoblastic Leukemia, Childhood B Acute Lymphoblastic Leukemia
Interventions
Cyclophosphamide, Cytarabine, Daunorubicin Hydrochloride, Dexamethasone, Doxorubicin Hydrochloride, Leucovorin Calcium, Mercaptopurine, Methotrexate, Pegaspargase, Prednisone, Radiation Therapy, Thioguanine, Vincristine Sulfate
Drug · Radiation
Lead sponsor
Children's Oncology Group
Network
Eligibility
1 Year to 30 Years
Enrollment
3,154 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2021
U.S. locations
208
States / cities
Birmingham, Alabama • Mobile, Alabama • Mesa, Arizona + 151 more
Conditions
Macular Edema, Uveitis
Interventions
Ozurdex Intravitreal Injection (0.7 mg)
Drug
Lead sponsor
Northern California Retina Vitreous Associates
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Mountain View, California
Active, not recruiting Phase 1Phase 2 Interventional

Ixazomib + Pomalidomide + Dexamethasone In MM

NCT04094961
Conditions
Multiple Myeloma, Multiple Myeloma in Relapse
Interventions
Ixazomib, Pomalidomide, Dexamethasone
Drug
Lead sponsor
Omar Nadeem, MD
Other
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Acute Lymphoblastic Leukemia, Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1
Interventions
Alemtuzumab, Allogeneic Hematopoietic Stem Cell Transplantation, Autologous Hematopoietic Stem Cell Transplantation, Cyclophosphamide, Cytarabine, Dasatinib, Daunorubicin Hydrochloride, Dexamethasone, Etoposide Phosphate, Filgrastim, Fludarabine Phosphate, In Vitro-Treated Peripheral Blood Stem Cell Transplantation, Laboratory Biomarker Analysis, Leucovorin Calcium, Melphalan, Mercaptopurine, Methotrexate, Pegfilgrastim, Pharmacological Study, Tacrolimus, Vincristine Sulfate
Biological · Procedure · Drug + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2021
U.S. locations
101
States / cities
Palo Alto, California • Aurora, Colorado • Boulder, Colorado + 68 more
Conditions
Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia, Mixed Phenotype Acute Leukemia, T Acute Lymphoblastic Leukemia
Interventions
Allogeneic Hematopoietic Stem Cell Transplantation, Calaspargase Pegol, Cyclophosphamide, Cytarabine, Daunorubicin Hydrochloride, Dexamethasone, Dexrazoxane Hydrochloride, Doxorubicin, Etoposide, Filgrastim, Ifosfamide, Imatinib Mesylate, Laboratory Biomarker Analysis, Leucovorin Calcium, Levoleucovorin, Mercaptopurine, Methotrexate, Methylprednisolone, Pegaspargase, Prednisolone, Questionnaire Administration, Therapeutic Hydrocortisone, Thioguanine, Vincristine Sulfate
Procedure · Drug · Biological + 1 more
Lead sponsor
Children's Oncology Group
Network
Eligibility
1 Year to 21 Years
Enrollment
352 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2034
U.S. locations
184
States / cities
Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 145 more
Conditions
Chemotherapy-induced Nausea and Vomiting
Interventions
Rolapitant, Granisetron, Dexamethasone, Placebo
Drug
Lead sponsor
Tesaro, Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,369 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Waltham, Massachusetts
Conditions
Advanced Malignant Neoplasm, Fatigue, Metastatic Malignant Neoplasm, Recurrent Malignant Neoplasm, Refractory Malignant Neoplasm
Interventions
Dexamethasone, Exercise Intervention, Laboratory Biomarker Analysis, Quality-of-Life Assessment, Questionnaire Administration
Drug · Behavioral · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2026
U.S. locations
1
States / cities
Houston, Texas
Conditions
Lymphoid Malignancies (New or Relapsed), Acute Lymphoblastic Leukemia, Burkitt Lymphoma, Lymphoblastic Lymphoma, Mantle Cell Lymphoma, Adult T-cell Leukemia/Lymphoma
Interventions
Hyper-CVAD, Sirolimus
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
2
States / cities
Philadelphia, Pennsylvania
Conditions
Multiple Myeloma
Interventions
Melflufen, Pomalidomide, Dexamethasone
Drug
Lead sponsor
Oncopeptides AB
Industry
Eligibility
18 Years and older
Enrollment
495 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
14
States / cities
Tucson, Arizona • Fresno, California • Gainesville, Florida + 11 more
Conditions
B Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia, BCR-ABL1-Like, Central Nervous System Leukemia, Testicular Leukemia
Interventions
Clofarabine, Cyclophosphamide, Cytarabine, Dasatinib, Daunorubicin Hydrochloride, Dexamethasone, Doxorubicin Hydrochloride, Etoposide, Hydrocortisone Sodium Succinate, Laboratory Biomarker Analysis, Leucovorin Calcium, Mercaptopurine, Methotrexate, Pegaspargase, Prednisone, Radiation Therapy, Thioguanine, Vincristine Sulfate
Drug · Other · Radiation
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
1 Year to 31 Years
Enrollment
5,949 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2026
U.S. locations
209
States / cities
Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 153 more
Conditions
Lymphoma
Interventions
Fludarabine, Mitoxantrone, Rituximab, Zevalin, Dexamethasone
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
60 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2021
U.S. locations
1
States / cities
Houston, Texas
Conditions
Plasma Cell Myeloma
Interventions
Belantamab Mafodotin, Dexamethasone, Pomalidomide
Biological · Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
1
States / cities
Atlanta, Georgia
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

TPI Medication Comparison - Ketorolac, Lidocaine, or Dexamethasone

NCT03028012
Conditions
Myofascial Pain
Interventions
Ketorolac, Lidocaine, Dexamethasone
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years to 100 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Salt Lake City, Utah
Conditions
DS Stage I Multiple Myeloma, DS Stage II Multiple Myeloma, DS Stage III Multiple Myeloma
Interventions
Dexamethasone, Laboratory Biomarker Analysis, Lenalidomide, Thalidomide
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
452 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2026
U.S. locations
138
States / cities
Birmingham, Alabama • Huntsville, Alabama • Anchorage, Alaska + 115 more
Conditions
Leukemia
Interventions
12-O-tetradecanoylphorbol-13-acetate, Dexamethasone, Choline magnesium trisalicylate
Drug
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
New Brunswick, New Jersey
Conditions
Ocular Disease Requiring Surgery
Interventions
DEXTENZA®
Drug
Lead sponsor
Nathan Steinle
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
3
States / cities
Paso Robles, California • San Luis Obispo, California • Santa Maria, California
Conditions
Leukemia, Lymphoma
Interventions
filgrastim, cyclophosphamide, cytarabine, dexamethasone, doxorubicin hydrochloride, etoposide, ifosfamide, leucovorin calcium, methotrexate, vincristine sulfate
Biological · Drug
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 22 Years
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2006
U.S. locations
104
States / cities
Birmingham, Alabama • Mobile, Alabama • Tucson, Arizona + 77 more